- Recce Pharmaceuticals (RCE) has reported further findings from its fee-for-service collaboration between CSIRO and the Doherty Institute
- The latest round of results are from ongoing testing of its anti-infective drug R237 against SARS-CoV-2, the virus that causes COVID-19
- According to RCE, the results confirm and extend the findings from testing in February, which found R327 to be 99.9 per cent effective against SARS-CoV-2 at higher doses
- On the basis of these findings, Recce has been issued a qualified recommendation to proceed to stage two of the programme
Read the Full Article on The Market Herald here
Recce Pharmaceuticals (ASX:RCE) moves to stage two anti-COVID screening with CSIRO
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
44.5¢ |
Change
0.080(21.9%) |
Mkt cap ! $128.6M | |||
| Open | High | Low | Value | Volume |
| 37.5¢ | 44.5¢ | 37.5¢ | $191.2K | 477.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 12222 | 44.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 45.0¢ | 10976 | 2 |
View Market Depth
| Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
| RCE (ASX) Chart |